ClinicalTrials.gg
CompletedNCT05723510Updated Dec 11, 2023

PK and PD Interaction Between Tegoprazan and NOACs After Multiple Oral Dosing in Healthy Volunteers

A Phase 1 interventional study of Tegoprazan 50mg and Edoxaban 60mg in Healthy, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by HK inno.N Corporation · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
19 Years to 54 Years
Sex
All
01

Study summary

This study aims to evaluate the effects of combination therapy of tegoprazan and novel oral anticoagulants (NOACs) on the pharmacokinetic and pharmacodynamic properties of NOACs in healthy adults.

Read the detailed description

A randomized, open-label, multiple-dose, two-arm, two-period crossover study

[Cohort 1] To evaluate the effects of combination therapy of tegoprazan and edoxaban on the pharmacokinetic and pharmacodynamic properties of edoxaban in healthy adults.

[Cohort 2] To evaluate the effects of combination therapy of tegoprazan and apixaban on the pharmacokinetic and pharmacodynamic properties of apixaban in healthy adults.

[Cohort 3] To evaluate the effects of combination therapy of tegoprazan and rivaroxaban on the pharmacokinetic and pharmacodynamic properties of rivaroxaban in healthy adults.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 54 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adults aged ≥ 19 years to \< 55 years at the time of screening
  2. Those with body weight ≥ 45 kg (but ≥ 60 kg for cohort 1 and cohort 2) and (BMI) in the range of 19.0 kg/m2 to 27.0 kg/m2 at the time of screening

    ☞ BMI = weight (kg) / height (m)2

  3. Those who have neither congenital/chronic disease (within recent 3 years) nor pathological symptoms/findings as a result of medical examination
  4. Those determined to be eligible for this study based on the findings of screening such as clinical laboratory tests (hematological test, blood chemistry test, blood coagulation test, urinalysis, test for viruses/bacteria, etc.), vital signs, and (ECG) which are performed by the investigator according to the properties of medicines
  5. Those who are fully informed of study purpose, procedures, etc., voluntarily decide to participate in this study, and sign an form (ICF) approved by the Institutional Review Board (IRB) of Jeonbuk National University Hospital, prior to participation in the study
  6. Those with a capability/willingness to participate throughout the study

Exclusion criteria

Exclusion Criteria:

  1. Medical history of blood, renal, endocrine, respiratory, gastrointestinal (peptic ulcer, etc.), urinary, cardiovascular, hepatic, psychiatric, neurological or immune disease (but except for history of simple dental treatment such as tartar, impacted teeth, and third molar teeth) or evidence thereof
  2. Previous history of gastrointestinal disease (except for esophageal disease such as esophageal achalasia or esophageal stricture, inflammatory bowel disease (Crohn's disease, ulcerative colitis)) or surgery (not including simple appendectomy, hernia surgery, tooth extraction, etc.) which may affect drug absorption
  3. Following findings of clinical laboratory tests:

    ☞ or AST value > twice the (ULN)

  4. History of periodic alcohol consumption exceeding 210 g/week within 6 months prior to screening (beer (5%) 1 glass (250 mL) = 10 g, soju (20%) 1 glass (50 mL) = 8 g, wine (12%) 1 glass (125 mL) = 12 g)
  5. Administration of another product within 6 months prior to the first dose of the investigational product
  6. History of serious alcohol or drug misuse and abuse within 1 year prior to screening
  7. Administration of drugs known to markedly induce or inhibit drug metabolizing enzymes within 30 days prior to the first dose of the investigational product
  8. History of smoked cigarettes ≥ 20 cigarettes/day within 6 months prior to screening
  9. Administration of a prescription or non-prescription drug within 10 days prior to the first dose of the investigational product
  10. Whole blood donation within 2 months prior to the first dose of the investigational product or apheresis donation within 1 month prior to the first dose of the investigational product
  11. Those who may be put at an increased risk due to the adminisration of the investigational product and study participation or have a severe acute/chronic medical or mental condition which may interfere with the interpretation of study results
  12. Patients with to tegoprazan, edoxaban, apixaban, rivaroxaban, etc. (e.g., asthma, acute rhinitis, nasal polyp, angioedema, urticaria, allergic reactions, etc.)
  13. Patients with a clinically significant bleeding
  14. Patients with hemostatic disorder and hepatic disease related to a clinically significant risk of bleeding
  15. Severe hepatic impairment
  16. Renal impairment ( \<60 ml/min/1.73m2)
  17. Hereditary problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
  18. Pregnant/breast-feeding women
  19. Those who cannot use medically acceptable methods throughout the study

    ▶ Medically acceptable contraceptive methods

    • Use of intrauterine device (IUD) showing a demonstrated pregnancy failure rate
    • Combined use of barrier contraceptive method (for male or female) and spermicide
    • Use of vasectomy, tubectomy/tubal ligation, or hysterectomy
  20. Those who are not eligible for the study in the judgment of the investigator
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Edoxaban 60mg

    Multiple dosing of edoxaban alone once daily for 5 days

    Drug: Edoxaban 60mg

  • Experimental
    Edoxaban 60mg + Tegoprazan 50mg

    Multiple dosing of edoxaban once daily in combination with tegoprazan once daily for 5 days

    Drug: Tegoprazan 50mg · Drug: Edoxaban 60mg

  • Experimental
    Apixaban 5mg

    Multiple dosing of apixaban alone twice daily for 5 days

    Drug: Apixaban 5mg

  • Experimental
    Apixaban 5mg + Tegoprazan 50mg

    Multiple dosing of apixaban twice daily in combination with tegoprazan once daily for 5 days

    Drug: Tegoprazan 50mg · Drug: Apixaban 5mg

  • Experimental
    Rivaroxaban 20mg

    Multiple dosing of rivaroxaban alone once daily for 5 days

    Drug: Rivaroxaban 20mg

  • Experimental
    Rivaroxaban 20mg + Tegoprazan 50mg

    Multiple dosing of rivaroxaban once daily in combination with tegoprazan once daily for 5 days

    Drug: Tegoprazan 50mg · Drug: Rivaroxaban 20mg

Interventions

  • Oral administration of one tablet of tegoprazan 50 mg once daily

    Also known as: K-CAB Tab. 50 mg

  • Oral administration of one tablet of edoxaban 60 mg once daily

    Also known as: Lixiana Tab. 60mg

  • Oral administration of one tablet of apixaban 5 mg twice daily

    Also known as: Eliquis Tab. 5 mg

  • Oral administration of one tablet of rivaroxaban 20 mg once daily

    Also known as: Xarelto Tab. 20 mg

06

What researchers measure

Primary outcomes

  1. AUCτ and Css,max of edoxaban

    Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of edoxaban

    Time frame: Pre-dose(0 hour) on 1D, 3D, and 4D for each period; pre-dose(0 hour) up to 48 hours after treatment on 5D for each period

  2. AUCτ and Css,max of apixaban

    Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of apixaban

    Time frame: Pre-dose (0 hour) in the morning on 1D and in the morning and afternoon on 4D for each period; pre-dose(0 hour) in the morning up to 48 hours after treatment on 5D for each period

  3. AUCτ and Css,max of rivaroxaban

    Area under the plasma concentration-time curve during a steady-state dosing interval (τ) and maximum plasma concentration at steady state of rivaroxaban

    Time frame: Pre-dose (0 hour) on 1D, 3D, and 4D for each period; pre-dose(0 hour) up to 48 hours after treatment on 5D for each period

  4. AUECτ and Emax of Anti-Factor Xa activity, PT, aPTT, and Prothrombin (INR)

    Area under the effect-time curve over the dosing interval (τ) at steady state and maximum effect of Anti-Factor Xa activity, PT, aPTT, and Prothrombin (INR)

    Time frame: Pre-dose (0 hour) up to 24 hours after treatment on 5D for each period

07

Study locations

1 site
  • Jeonbuk National University Hospital
    Jeonju, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2023 to primary completion in Jul 2023, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 10, 2023
StartActual
Mar 6, 2023
Primary completionActual
Jul 17, 2023
CompletionActual
Jul 24, 2023
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05723510
Responsible party
Sponsor
First posted
Feb 10, 2023
Start date
Mar 6, 2023
Primary completion
Jul 17, 2023
Completion
Jul 24, 2023
Last update
Dec 11, 2023

Study contacts

Min-Gul Kim
principal investigator · Clinical Pharmacology Center, Jeonbuk National University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tegoprazan · Edoxaban · Apixaban · Rivaroxaban

Start the discussion